Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

To evaluate the efficacy of new generation extended-depth-of-focus IOL

Search Title by author or title

Session Details

Session Title: Pseudophakic IOLs: Enlarged Depth of Focus

Session Date/Time: Tuesday 10/10/2017 | 08:30-10:30

Paper Time: 09:00

Venue: Room 3.1

First Author: : K.Ramamoorthy INDIA

Co Author(s): :    N. Madhivanan   P. Nivean   J. Reddy   M. Rajan           

Abstract Details

Purpose:

To evaluate the visual acuity for near, intermediate and distance and subjective visual outcomes in patients who had new generation foldable Infocus IOL implantation.

Setting:

MN Eye Hospital, tertiary eye hospital, Chennai, India

Methods:

31 patients of age 40 and above with uncomplicated senile cataract and with astigmatism less than 1D underwent standard 2.8mm Phacoemulsification with new generation IOL (Supraphob Infocus) in their eyes. Visual acuity for near, intermediate and distance was measured using Snellens, Goodlite and Logmar chart respectively. Contrast sensitivity was measured using Mars contrast chart. Patient satisfaction with their vision, visual symptoms and spectacle dependence was assessed using a standardized questionnaire.

Results:

91% of patients had visual acuity between 0 to 0.17, 87% of them had Intermediate vision of 0 to 0.17 and 71% of them had a near vision of N6 with a p-value of 0.0001, 0.0241 and 0.000004 which was statistically significant. 75% of the patients had a contrast sensitivity of 1.92 to 1.72. 87% of the patients had no spectacle dependency for near or distance. No patients complained of glare or halos.

Conclusions:

New Generation Extended depth of focus IOL is a good option for extended range of correction with excellent visual outcomes for distance, intermediate and near vision without the compromise of contrast sensitivity which also minimises glare and halos.

Financial Disclosure:

NONE

Back to previous